IL162596A0 - 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists - Google Patents
1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonistsInfo
- Publication number
- IL162596A0 IL162596A0 IL16259602A IL16259602A IL162596A0 IL 162596 A0 IL162596 A0 IL 162596A0 IL 16259602 A IL16259602 A IL 16259602A IL 16259602 A IL16259602 A IL 16259602A IL 162596 A0 IL162596 A0 IL 162596A0
- Authority
- IL
- Israel
- Prior art keywords
- ntagonists
- azoniabicyclo
- octane
- alkyl
- muscarinic receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200200043 | 2001-12-20 | ||
PCT/EP2002/014470 WO2003053966A2 (en) | 2001-12-20 | 2002-12-18 | 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162596A0 true IL162596A0 (en) | 2005-11-20 |
Family
ID=32480019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16259602A IL162596A0 (en) | 2001-12-20 | 2002-12-18 | 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists |
Country Status (21)
Country | Link |
---|---|
US (1) | US7452904B2 (pt) |
EP (1) | EP1461336B1 (pt) |
JP (1) | JP4505227B2 (pt) |
KR (1) | KR100944580B1 (pt) |
CN (1) | CN1832948B (pt) |
BR (1) | BR0215348A (pt) |
CA (1) | CA2470956C (pt) |
EA (1) | EA006505B1 (pt) |
ES (1) | ES2425347T3 (pt) |
GE (1) | GEP20063958B (pt) |
HK (1) | HK1070057A1 (pt) |
HR (1) | HRP20040661A2 (pt) |
HU (1) | HUP0500107A3 (pt) |
IL (1) | IL162596A0 (pt) |
MA (1) | MA26385A1 (pt) |
MX (1) | MXPA04006206A (pt) |
NO (1) | NO329664B1 (pt) |
PL (1) | PL211250B1 (pt) |
RS (1) | RS52522B (pt) |
UA (1) | UA76571C2 (pt) |
WO (1) | WO2003053966A2 (pt) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE20122417U1 (de) * | 2000-06-27 | 2005-08-04 | Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat | Von Arylalkylaminen abgeleitete Carbamate |
IL156499A0 (en) * | 2000-12-22 | 2004-01-04 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as m3 antagonists |
ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
AR044134A1 (es) | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
WO2004106333A1 (en) | 2003-05-28 | 2004-12-09 | Theravance, Inc. | Azabicycloalkane compounds as muscarinic receptor antagonists |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
UY28871A1 (es) * | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | Antagonistas del receptor de acetilcolina muscarinico |
JP2007537261A (ja) * | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
ES2246170B1 (es) * | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
ES2313401T3 (es) | 2004-07-30 | 2009-03-01 | Laboratorios Salvat, S.A. | Derivados de tirosina como moduladores de ppar-gamma. |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
MX2008002805A (es) | 2005-09-21 | 2008-04-07 | Pfizer Ltd | Derivados de carboxamida como antagonistas del receptor muscarinico. |
EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
PL2322525T3 (pl) | 2006-04-21 | 2014-03-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub> |
EP1882691A1 (en) | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine derivatives as M3 antagonists |
BRPI0717564A2 (pt) | 2006-09-29 | 2013-10-22 | Novartis Ag | Pirazolopirimidinas como inibidores de pi3k lipídeo cinase |
EP2076261A2 (en) * | 2006-10-03 | 2009-07-08 | Ranbaxy Laboratories, Ltd. | Muscarinic receptor antagonists |
RS51644B (en) | 2007-01-10 | 2011-10-31 | Irm Llc. | UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES |
PL2155721T3 (pl) | 2007-05-07 | 2011-07-29 | Novartis Ag | Związki organiczne |
EP2065385A1 (en) * | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
PT2444120T (pt) | 2007-12-10 | 2018-01-03 | Novartis Ag | Análogos da amilorida espirocíclicos como bloqueadores de enac |
KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
EP2080523A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
EP2080508A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
EP2080507A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical formulations comprising an anticholinergic drug |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
EP2154136A1 (en) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
ES2396023T3 (es) | 2009-01-29 | 2013-02-18 | Novartis Ag | Bencimidazoles sustituidos para el tratamiento de astrocitomas |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | 複素環式化合物およびそれらの使用 |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
EP2585458B1 (en) | 2010-06-22 | 2015-01-07 | Chiesi Farmaceutici S.p.A. | Alkaloid aminoester derivatives and medicinal compositions thereof |
CN102947298B (zh) | 2010-06-22 | 2016-03-02 | 奇斯药制品公司 | 生物碱氨基酯衍生物及其药物组合物 |
CA2803459A1 (en) | 2010-06-22 | 2011-12-29 | Chiesi Farmaceutici S.P.A. | Alkaloid aminoester derivatives and medicinal compositions thereof |
AU2011269238A1 (en) | 2010-06-22 | 2013-01-10 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising an antimuscarinic drug |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EP2640721B1 (en) | 2010-11-16 | 2018-06-06 | Texas Heart Institute | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
RU2585767C2 (ru) | 2010-11-26 | 2016-06-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные глицина и их применение в качестве антагонистов мускариновых рецепторов |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
US20120220557A1 (en) | 2011-02-17 | 2012-08-30 | Chiesi Farmaceutici S.P.A. | Liquid propellant-free formulation comprising an antimuscarinic drug |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
RU2611627C2 (ru) | 2011-04-29 | 2017-02-28 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Алкалоидный эфир и карбаматные производные и их медицинские композиции |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
JP5957526B2 (ja) | 2011-09-15 | 2016-07-27 | ノバルティス アーゲー | チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン |
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
CN104011043B (zh) | 2011-12-30 | 2016-11-16 | 奇斯药制品公司 | 作为抗毒蕈碱剂的1-氮杂杂环基乙酸的奎宁环酯、它们的制备方法及其药用组合物 |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
CN106458979B (zh) | 2014-04-24 | 2020-03-27 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物 |
KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
KR20240052079A (ko) | 2015-04-29 | 2024-04-22 | 7 힐즈 인터레스츠 엘엘씨 | 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법 |
US11311619B2 (en) | 2016-04-28 | 2022-04-26 | 7 Hills Pharma Inc. and Texas Heart Institute | Integrin activator vaccine compositions |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
JOP20220044A1 (ar) | 2019-08-28 | 2023-01-30 | Novartis Ag | مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0495071A (ja) * | 1990-08-10 | 1992-03-27 | Kyorin Pharmaceut Co Ltd | カルバミン酸誘導体 |
AU7545894A (en) * | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
AU685225B2 (en) * | 1994-02-10 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
MXPA02005596A (es) * | 1999-12-07 | 2004-09-10 | Theravance Inc | Derivados de carbamato con actividad antagonista para el rerceptor muscarinico. |
DE20122417U1 (de) * | 2000-06-27 | 2005-08-04 | Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat | Von Arylalkylaminen abgeleitete Carbamate |
IL156499A0 (en) * | 2000-12-22 | 2004-01-04 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as m3 antagonists |
-
2002
- 2002-12-18 MX MXPA04006206A patent/MXPA04006206A/es active IP Right Grant
- 2002-12-18 HU HU0500107A patent/HUP0500107A3/hu unknown
- 2002-12-18 IL IL16259602A patent/IL162596A0/xx not_active IP Right Cessation
- 2002-12-18 EA EA200400832A patent/EA006505B1/ru not_active IP Right Cessation
- 2002-12-18 RS YU53904A patent/RS52522B/en unknown
- 2002-12-18 KR KR1020047009786A patent/KR100944580B1/ko not_active IP Right Cessation
- 2002-12-18 EP EP02796673.8A patent/EP1461336B1/en not_active Expired - Lifetime
- 2002-12-18 BR BR0215348-3A patent/BR0215348A/pt not_active IP Right Cessation
- 2002-12-18 US US10/499,130 patent/US7452904B2/en not_active Expired - Fee Related
- 2002-12-18 CN CN028278364A patent/CN1832948B/zh not_active Expired - Fee Related
- 2002-12-18 WO PCT/EP2002/014470 patent/WO2003053966A2/en active Search and Examination
- 2002-12-18 UA UA20040706015A patent/UA76571C2/uk unknown
- 2002-12-18 GE GE5649A patent/GEP20063958B/en unknown
- 2002-12-18 JP JP2003554682A patent/JP4505227B2/ja not_active Expired - Fee Related
- 2002-12-18 CA CA2470956A patent/CA2470956C/en not_active Expired - Fee Related
- 2002-12-18 PL PL370972A patent/PL211250B1/pl not_active IP Right Cessation
- 2002-12-18 ES ES02796673T patent/ES2425347T3/es not_active Expired - Lifetime
-
2004
- 2004-07-16 MA MA27789A patent/MA26385A1/fr unknown
- 2004-07-19 NO NO20043064A patent/NO329664B1/no not_active IP Right Cessation
- 2004-07-19 HR HR20040661A patent/HRP20040661A2/hr not_active Application Discontinuation
-
2005
- 2005-03-23 HK HK05102521.9A patent/HK1070057A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162596A0 (en) | 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists | |
HK1054768A1 (en) | Damping intermediate pillar and damping structure using the same. | |
IL151829A0 (en) | Carbamate derivatives and pharmaceutical compositions containing the same | |
HUP0402113A3 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof | |
HK1055120A1 (en) | Quinuclidine carbamate derivatives and their use as m3 antagonists | |
IL161881A (en) | N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives | |
IL148545A0 (en) | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof | |
HUP0402489A3 (en) | 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | |
AU6031001A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
HUP0401638A3 (en) | Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same | |
IL156161A0 (en) | Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors | |
IL152701A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
AU4923200A (en) | Isothiazolecarboxamides and their use as microbicides | |
HK1081954A1 (en) | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | |
PL370799A1 (en) | Aminotetralin derivatives as muscarinic receptor antagonists | |
HUP0303155A3 (en) | 2-thio-substituted imidazole derivatives, the use thereof and pharmaceutical compositions containing them | |
IL159006A0 (en) | Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same | |
PL354921A1 (en) | Substituted phenyluracils and their use as herbicides | |
HUP0600238A3 (en) | Benzothiazole- and benzoxazole-4,7-dione derivatives and their use | |
AU5786300A (en) | Muscarinic antagonists | |
PL359366A1 (en) | Substituted heteroaryloxyacetanilides and their use as herbicides | |
MXPA02005731A (es) | Moleculas similares al antagonista del receptor de interleucina-1 y usos de las mismas. | |
GB0020573D0 (en) | The personal head rest | |
SI1453783T1 (sl) | Substituirani aril-cikloalkani in njihova uporaba kot sredstva proti raku | |
MXPA02005775A (es) | Moleculas ralacionadas con el antagonista del receptor de la interleucina-1 y usos de las mismas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |